389 completed, 42 terminated, 32 unknown, 15 withdrawn. 481 Phase 2, 57 Phase 1, 45 Phase 3.
Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV Glecaprevir/pibrentasvir - Hepatitis C | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2026-06-25 | 2026-08-14 |
| Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder Glecaprevir/pibrentasvir, Placebo - PTSD | Phase 2 / Phase 3 | Unknown | White River Junction Veterans Affairs Medical Center | 92 | 2023-12-18 | 2025-04-24 |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD | Phase 2 / Phase 3 | Completed | White River Junction Veterans Affairs Medical Center | 10 | 2023-04-01 | 2024-08-29 |
| Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone MTL-CEBPA, Sorafenib - Hepatocellular Carcinoma, Hepatitis B | Phase 2 | Completed | Mina Alpha Limited | 8 | 2022-01-01 | 2025-03-06 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor glecaprevir/pibrentasvir (GLE/PIB) - Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of | Phase 1 / Phase 2 | Completed | University of California, San Diego | 12 | 2021-05-28 | 2022-05-24 |
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 24 | 2020-07-06 | 2020-09-10 |
| Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Glecaprevir/Pibrentasvir (G/P) - Hepatitis C Infection, HIV Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 45 | 2019-11-20 | 2024-07-11 |
| The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients sofosbuvir/velpatasvir - Liver Transplant, Hepatitis C | Phase 2 | Completed | Fernanda P Silveira, MD, MS | 5 | 2019-08-15 | 2026-04-30 |
| Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA). Prolonged-Release Pirfenidone - Liver Cirrhosis, Hepatitis C, Chronic | Phase 2 | Unknown | University of Guadalajara | 60 | 2019-08-01 | 2023-07-06 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 10 | 2019-06-20 | 2020-05-04 |
| The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients sofosbuvir/velpatasvir - Kidney Transplantation, Hepatitis C | Phase 2 | Active not recruiting | Amit D Tevar, MD | 30 | 2019-05-29 | 2025-11-06 |
| Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Sofosbuvir and Velpatasvir - Hepatitis C, Acute Hepatitis C | Phase 2 | Completed | Hannover Medical School | 20 | 2019-05-28 | 2021-07-06 |
| Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection SOF+DCV+CDI-31244, SOF+DCV+CDI-31244+ASV - HCV Infection | Phase 2 | Withdrawn | Humanity & Health Medical Group Limited | 2019-05-01 | 2020-05-07 | |
| A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis Ambrisentan - Cirrhosis, Portal Hypertension | Phase 2 | Terminated | Noorik Biopharmaceuticals AG | 19 | 2019-04-11 | 2021-02-26 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection | Phase 2 | Unknown | Ginkgopharma CO., LTD | 36 | 2019-04-03 | 2019-10-01 |
| SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic | Phase 2 / Phase 3 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 440 | 2019-03-29 | 2019-08-28 |
Showing 20 of 481. Sign in to see all of them.
Hepatitis C, Chronic (227) · HIV Infections (29) · Hepatitis (28) · Liver Diseases (21) · Fibrosis (17) · Liver Cirrhosis (14) · Virus Diseases (13) · Hepatitis, Chronic (11) · Hepatitis B (9) · Bronchiolitis Obliterans Syndrome (6) · Carcinoma, Hepatocellular (6) · Acquired Immunodeficiency Syndrome (5) · Infections (5) · Coinfection (4)
Blood-Borne Infections (481) · Communicable Diseases (480) · Digestive System Diseases (478) · Flaviviridae Infections (478) · Hepatitis, Viral, Human (478) · RNA Virus Infections (477) · Infections (476) · Virus Diseases (468) · Liver Diseases (460) · Hepatitis (453) · Pathological Conditions, Signs and Symptoms (259) · Pathologic Processes (258) · Disease Attributes (238) · Chronic Disease (236) · Hepatitis, Chronic (224)
Ribavirin (227) · peginterferon alfa-2a (106) · Sofosbuvir (52) · peginterferon alfa-2b (33) · daclatasvir (32) · Ritonavir (25) · ledipasvir, sofosbuvir drug combination (24) · telaprevir (23) · Simeprevir (19) · paritaprevir (19) · grazoprevir (18) · sofosbuvir-velpatasvir drug combination (18) · ombitasvir (16) · dasabuvir (12) · elbasvir (12)
Gilead Sciences (53) · Merck Sharp & Dohme LLC (40) · Bristol-Myers Squibb (28) · National Institute of Allergy and Infectious Diseases (NIAID) (18) · Hoffmann-La Roche (17) · Vertex Pharmaceuticals Incorporated (15) · AbbVie (14) · ANRS, Emerging Infectious Diseases (11) · AbbVie (prior sponsor, Abbott) (11) · Boehringer Ingelheim (9) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (8) · Romark Laboratories L.C. (6) · Conatus Pharmaceuticals Inc. (5) · French National Agency for Research on AIDS and Viral Hepatitis (5) · BioWest Therapeutics Inc (4)
United States (239) · France (74) · Puerto Rico (70) · Germany (66) · Canada (50) · Spain (44) · United Kingdom (39) · Australia (35) · New Zealand (32) · Belgium (29) · Italy (28) · Poland (25) · Austria (20) · Egypt (19) · Taiwan (16)
Asem Elfert, MD (4) · Daniel Cohen, MD (4) · Jim Pankovich (4) · Robert H. Hyland, DPhil (4)
PMID 28193518, PMID 30012435, PMID 30923816, PMID 30977945, PMID 24154738, PMID 24209977, PMID 24983020, PMID 25164700, PMID 25445400, PMID 25830171, PMID 26596948, PMID 26683763, PMID 26691547, PMID 26752189, PMID 28412293, PMID 28802814, PMID 28802816, PMID 31108015, PMID 31568620, PMID 15282352, PMID 15316341, PMID 15374882, PMID 15563253, PMID 15667486, PMID 15685543, PMID 15820563, PMID 15867490, PMID 16115185, PMID 16439867, PMID 16544259, PMID 16987047, PMID 17058240, PMID 17147494, PMID 17200799, PMID 17263626, PMID 17582705, PMID 17721093, PMID 17721100, PMID 18184077, PMID 18435468, PMID 18666223, PMID 18771667, PMID 19268724, PMID 19403902, PMID 19403903, PMID 19447518, PMID 19594300, PMID 19797971, PMID 19833404, PMID 19852040
2014 (12), 2015 (11), 2009 (9), 2016 (8), 2008 (4), 2018 (3), 2004 (2), 2017 (2), 2019 (2), R01DA026727 (2), UM1AI068636 (2), 2005 (1), N01CN35160 (1), P50AT000009 (1), R01AI049141 (1)